Vyera Pharmaceuticals
| Company type | Private |
|---|---|
| Industry | pharmaceuticals |
| Founded | February 2015 |
| Founder | |
| Defunct | 2024 |
| Headquarters | New York City and Zug, Switzerland |
Key people | Justin Garrett Chief Executive Officer |
| Products | Vecamyl, Daraprim |
| Website | www |
Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.
The company has two marketed products: Daraprim (pyrimethamine), for the treatment of toxoplasmosis associated with HIV/AIDS, and Vecamyl (mecamylamine hydrochloride) for the treatment of hypertension. The company was widely criticized for raising the price of daraprim by 5456% following its acquisition of rights to the drug in 2015. The company's stock price dropped around 10% after the price increase of the drug. CEO Martin Shkreli faced immense criticism for his actions. The company was previously named after Alan Turing, the computer scientist.
On May 10, 2023, Vyera filed for Chapter 11 bankruptcy.